J. Goldman & Co LP - TREVI THERAPEUTICS INC ownership

TREVI THERAPEUTICS INC's ticker is TRVI and the CUSIP is 89532M101. A total of 37 filers reported holding TREVI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 43.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
J. Goldman & Co LP ownership history of TREVI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$300,563
-8.8%
137,8730.0%0.01%
-8.3%
Q2 2023$329,516
+99.7%
137,873
+54.6%
0.01%
+71.4%
Q1 2023$164,998
-4.1%
89,1880.0%0.01%
-12.5%
Q4 2022$172,133
+25.6%
89,1880.0%0.01%
+14.3%
Q3 2022$137,000
-63.9%
89,188
-33.9%
0.01%
-61.1%
Q2 2022$379,000135,0000.02%
Other shareholders
TREVI THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
NEA Management Company, LLC 11,370,376$24,787,4201.91%
Fairmount Funds Management LLC 5,163,287$11,255,9661.35%
Opaleye Management Inc. 1,705,900$3,718,8621.21%
Frazier Life Sciences Management, L.P. 6,881,090$15,000,7761.00%
VR Adviser, LLC 3,422,397$7,460,8250.78%
SILVERARC CAPITAL MANAGEMENT, LLC 927,415$2,021,7650.61%
Rubric Capital Management LP 5,684,420$12,392,0360.46%
Tejara Capital Ltd 180,227$392,8950.22%
PFS Partners, LLC 100,000$218,0000.19%
WealthTrust Axiom LLC 93,500$203,8300.07%
View complete list of TREVI THERAPEUTICS INC shareholders